APR 11, 2020 9:22 PM PDT

Promising Experimental Anti-Malarial Drug

WRITTEN BY: Nouran Amin

At St. Jude Children’s Research Hospital, researchers discovered a fast-acting anti-malarial compound with promising effectiveness in human trials—findings were published in the journal Lancet Infectious Diseases.

"The results support further development of the compound SJ733 as a fast-acting component of combination anti-malarial therapy," said corresponding author Aditya Gaur, M.D., of the St. Jude Department of Infectious Diseases. "The drug was well tolerated and well absorbed with a rapid anti-parasitic effect." Gaur and James McCarthy, M.D., MBBS, of QIMR Berghofer Medical Research Institute, Australia, are the co-first authors.

Scientists are hopeful to investigate methods that can extend blood levels of SJ733 and enhance it’s actions in patients with malaria

Caused by patristic infection, malaria is transmitted by mosquitos and targets the red blood cells.

Learn more about malaria:

"Safe and effective anti-malarial drugs that work by new mechanisms are critically needed to combat drug-resistant disease," said senior author R. Kip Guy, Ph.D., dean of the University of Kentucky College of Pharmacy. Guy led the anti-malarial drug-discovery effort and preclinical development of SJ733 while chair of the St. Jude Department of Chemical Biology and Therapeutics. The preclinical trials showed that SJ733 worked against malaria parasites that are resistant to current frontline drugs.

One of the first anti-malarial compounds, SJ733 works by disrupting the malaria parasite's ability in removing the excess sodium from red blood cells. When sodium builds up, infected cells become less flexible. No side-effects were reported through SJ733 treatment.

Source: Science Daily

 

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
MAY 12, 2021
Technology
Belkin Laser Completes Enrollment for Trial Studying New Glaucoma Laser Treatment
MAY 12, 2021
Belkin Laser Completes Enrollment for Trial Studying New Glaucoma Laser Treatment
Belkin Laser, a small Israel-based biotechnology company, has announced that it has completed enrollment for its pivotal ...
MAY 12, 2021
Cardiology
Reversing the Heart Damage Seen in Marfan Syndrome
MAY 12, 2021
Reversing the Heart Damage Seen in Marfan Syndrome
Marfan syndrome is a genetic disorder that disrupts the connective tissues that anchor and link the body's organs, affec ...
JUN 24, 2021
Immunology
Should We Rethink COVID Vaccine Recipes?
JUN 24, 2021
Should We Rethink COVID Vaccine Recipes?
In a study reported in the journal Cell, immunologists provide evidence for an Achilles’ heel in current COVI ...
JUN 29, 2021
Microbiology
Gut Fungi May Be an Untapped Reservoir of Antibiotics
JUN 29, 2021
Gut Fungi May Be an Untapped Reservoir of Antibiotics
Viruses are not the only microbes that can cause serious public health problems. Researchers have been warning about a p ...
JUL 16, 2021
Drug Discovery & Development
Machine Learning Ranks Cancer Drugs by Efficacy
JUL 16, 2021
Machine Learning Ranks Cancer Drugs by Efficacy
A machine learning algorithm developed by researchers at the Queen Mary University of London in the UK can rank cancer d ...
JUL 20, 2021
Technology
Artificial Intelligence Predicts Which Drug Candidates Will Be Successful In Clinical Trials
JUL 20, 2021
Artificial Intelligence Predicts Which Drug Candidates Will Be Successful In Clinical Trials
Researchers are leveraging artificial intelligence and machine learning to help improve the rate at which drugs move suc ...
Loading Comments...